Drug

Allist's Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive
Allist PharmaceuticalsCancer

Allist’s Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that the Phase 3 FURVENT trial (NCT05607550) evaluating firmonertinib monotherapy in previously untreated, locally advanced or metastatic non‑squamous NSCLC harboring EGFR exon 20…

anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China's First PPARγ Inhibitor to Enter Clinical Development

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China’s First PPARγ Inhibitor to Enter Clinical Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerClinical trial approval / initiation

Henlius Biotech Initiates China Dosing in Phase II/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC

Auto-immuneClinical trial approval / initiation

Hengrui Pharmaceuticals Receives NMPA Approval to Study SHR-1819 in Pediatric Atopic Dermatitis, Challenging Sanofi’s Dupilumab

Academic conferenceChia Tai Tianqing Pharmaceutical

Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026

Academic conferenceCancer

Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026

Show More